What's the patent expiration date for semaglutide?

When Does the Semaglutide Patent Expire?

According to DrugPatentWatch.com [1], the semaglutide patent, owned by Novo Nordisk, is set to expire in 2030 for the injectable formulation and in 2034 for the oral formulation.

Why is Semaglutide Patented?

Semaglutide is a GLP-1 receptor agonist approved for the treatment of type 2 diabetes and obesity. Novo Nordisk holds several patents for semaglutide, which protect the company's exclusivity for the drug [2].

How Will Patent Expiration Impact Semaglutide?

Patent expiration could allow generic versions of semaglutide to enter the market, potentially increasing competition and reducing prices [3]. This could also impact Novo Nordisk's sales and profitability for semaglutide.

Can Biosimilars Enter Before Patent Expiry?

Under the Biologics Price Competition and Innovation Act (BPCIA), biosimilars can be approved before the reference product's patent expires, provided they demonstrate biosimilarity and have no clinically meaningful differences [4].

When Will Semaglutide Biosimilars Enter the Market?

Several biosimilars to semaglutide are in development, but their approval and availability will depend on various regulatory and commercial factors [5].

Sources:

[1] DrugPatentWatch.com - Patents for Semaglutide https://www.drugpatentwatch.com/pharma/semaglutide.

[2] Patents owned by Novo Nordisk for semaglutide, listed on DrugPatentWatch.com.

[3] Impact of patent expiration on pharmaceutical markets, as discussed on PubMed.

[4] FDA - Biosimilars, guidance documents https://www.fda.gov/biologics-blood-vaccines/guidance-compliance-regulatory-information/biosimilars-guidance-documents.

[5] Biosimilars in development for semaglutide, listed on ClinCalc.com.